Strategies to incorporate pharmacoeconomics into pharmacotherapy

Slides:



Advertisements
Similar presentations
What is a review? An article which looks at a question or subject and seeks to summarise and bring together evidence on a health topic.
Advertisements

Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Designing Clinical Research Studies An overview S.F. O’Brien.
Study Designs in Epidemiologic
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
QUASI-EXPERIMENTAL STUDY DESIGNS IN EVALUATING MEDICINES USE INTERVENTIONS 1 Lloyd Matowe 2 Craig Ramsay 1 Faculty of Pharmacy, Kuwait University 2 HSRU,
Sensitivity Analysis for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Reading the Dental Literature
Estimation of Sample Size
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Part 3 of 3 By: Danielle Davidov, PhD & Steve Davis, MSW, MPA INTRODUCTION TO RESEARCH: SAMPLING & DESIGN.
Clinical Pharmacy Basma Y. Kentab MSc..
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
Intervention Studies Principles of Epidemiology Lecture 10 Dona Schneider, PhD, MPH, FACE.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 7: Gathering Evidence for Practice.
Presenter-Dr. L.Karthiyayini Moderator- Dr. Abhishek Raut
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Study Designs in Epidemiologic
Study Designs for Clinical and Epidemiological Research Carla J. Alvarado, MS, CIC University of Wisconsin-Madison (608)
EXPERIMENTAL EPIDEMIOLOGY
Matching Analyses to Decisions: Can we Ever Make Economic Evaluations Generalisable Across Jurisdictions? Mark Sculpher Mike Drummond Centre for Health.
Research Design Evidence Based Medicine Concepts and Glossary.
Unit 11: Evaluating Epidemiologic Literature. Unit 11 Learning Objectives: 1. Recognize uniform guidelines used in preparing manuscripts for publication.
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
Evidence Based Practice (EBP) Riphah College of Rehabilitation Sciences(RCRS) Riphah International University Islamabad.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Presentation Developed for the Academy of Managed Care Pharmacy
Introduction to General Epidemiology (2) By: Dr. Khalid El Tohami.
PRAGMATIC Study Designs: Elderly Cancer Trials
Copyright © Springer Publishing Company, LLC. All Rights Reserved. EVIDENCE-BASED TEACHING IN NURSING – Chapter 15 –
Study Design: Making research pretty Adam P. Sima, PhD July 13, 2016
Quantitative Methods for Business Studies
Some epidemiological principles and methods
HEALTH ECONOMICS BASICS
Descriptive study design
Lecture 15 Assoc. Prof. Sencer Ecer HEALTH ECONOMICS
Types of Research Studies Architecture of Clinical Research
Principles of Quantitative Research
Evidence-based Medicine
Present: Disease Past: Exposure
Chapter 11 Audit sampling
Siriporn Poripussarakul, Mahidol University, Thailand
Clinical Studies Continuum
Within Trial Decisions: Unblinding and Termination
Clinical practice guidelines and Clinical audit
Supplementary Table 1. PRISMA checklist
Clinical Study Results Publication
Quality Risk Management
Auditing & Investigations I
AXIS critical Appraisal of cross sectional Studies
Critical Reading of Clinical Study Results
Some Epidemiological Studies
Chapter Three Research Design.
Professor S K Dubey,VSM Amity School of Business
11/20/2018 Study Types.
Data and Data Collection
Critical Appraisal วิจารณญาณ
Evidence Based Practice
Interpreting Epidemiologic Results.
EPIDEMIOLOGY AS A TOOL TO EVALUATE QUALITY OF CARE
What is a review? An article which looks at a question or subject and seeks to summarise and bring together evidence on a health topic. Ask What is a review?
Level of Evidence Lecture 4.
Meta-analysis, systematic reviews and research syntheses
Research design and techniques Workshop ICBEDC 2010
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Strategies to incorporate pharmacoeconomics into pharmacotherapy Presented by: LALIT KUMAR(10/MPH/16) M.Pharm Ist year Clinical Research DIPSAR

CONTENTS INTRODUCTION TYPES OF STRATEGIES CONCLUSION REFERENCES

INTRODUCTION Various strategies are available to incorporate pharmacoeconomics into pharmacotherapy. Popular strategies for applying pharmacoeconomics to assess the value of pharmaceutical products and services are as follows: 1. The results of published pharmacoeconomic studies. 2. Building economic models. 3. Conducting pharmacoeconomic research.

CONT… STRATEGY ADVANTAGES DISADVANTAGES 1.USE PUBLISHED LITERATURE. 2.BUILD AN ECONOMIC MODEL QUICK RESULT S FROM RCT INEXPENSIVE DIFFICULT TO GENERALIZE RESULTS. SUBJECT TO PEER REVIEW MAY NOT BE COMPARATIVE MISUSE OF ITEMS DEPEND ON ASSUMPTIONS RELATIVELY INEXPENSIVE CONTROVERSIAL YIELD ORGANISATION SPECIFIC RESULTS POTENTIAL FOR RESEARCH BIAS BRIDGES EFFICACY AND EFFECTIVENESS

CONT… STRATEGY ADVANTAGES DISADVANTAGES 3.CONDUCT A PHARMACOECONOMIC STUDY. FLEXIBLE EXPENSIVE USUALLY COMPARATIVE TIME CONSUMING YIELD ORGANISATION SPECIFIC DATA. DIFFICULT TO CONTROL AND RANDOMIZE. DATA FROM MULTIPLE SOURCE CAN BE USED. POTENTIAL FOR PATIENT SELECTION BIAS,SMALL SAMPLE SIZE.

USE THE PHARMACOECONOMIC LITERATURE Many pharmacoeconomic analyses are published in primary medical and pharmacy literature sources. The eagerness to conduct pharmacoeconomic evaluations of drugs often exceeds the quality of these evaluations. To use this literature as an aid in clinical decision making, it must be (1) critically evaluated for quality and rigor and (2) interpreted correctly.

Basic Criteria for Evaluation of Pharmacoeconomic Literature Objective What is the question(s) being considered? Is the question clear, defined, and measurable? Perspective What is/are the perspective(s) of the analysis? Is the perspective appropriate given the scope of the problem? Pharmacoeconomic method What pharmacoeconomic tool was used? Is it appropriate given the problem? Is it actually what was conducted? Study design What was the study design? What were the data sources? Is the evaluation suitable if carried out in a clinical trial?

Cont… Costs and consequences What are the costs and consequences (outcomes) included? Are the costs and outcomes relevant to the perspective chosen? Do they include negative outcomes (failures, ADRs)? How were they valued? Were costs and consequences measured in the appropriate physical units? Discounting Was the study performed over time? Were costs and consequences that occur in the future discounted to their present value? Was any justification given for the discount rate used? Results Are the results accurate and practical for medical decision makers? Were the appropriate statistical analyses performed? Was an incremental cost analysis performed?

Cont… Sensitivity analysis Are the cost ranges for significant variables tested for sensitivity? Are the appropriate and relevant variables varied? Do the findings follow the anticipated trend? Conclusions Are the conclusions of the study justified? Is it possible to extrapolate the conclusions to daily clinical practice? Sponsorship Was there any bias due to the sponsorship of the study?

BUILD AN ECONOMIC MODEL Studies that model the economic impact of a pharmaceutical product or service on a defined population are increasing in popularity. Modeling studies use existing clinical and/or epidemiologic data to project future outcomes. Pharmacoeconomic models are often broadly defined to include: 1.Decision analysis 2.Markov models 3.Multivariate regression analysis 4.Basic spreadsheet analyses.

CLINICAL DECISION ANALYSIS Decision analysis is a tool that allow users to apply Evidence based medicine to make informed and objective clinical decisions when faced with complex situations. A decision tree ,together with literature derived probability and defined outcome value is used to model a given problem.

MARKOV MODELS Markov models is another method of decision analysis that provides an alternative way to arrange the decision process so that clinical outcomes and time-dependent risk changes are managed efficiently. The Markov model is designed to simulate the most important aspects of a disease and can be used to estimate the long-term clinical, humanistic, and economic dimensions of the disease.

Multivariate regression analysis Multivariate regression is a technique that estimates a single regression model with more than one outcome variable. When there is more than one predictor variable in a multivariate regression model, the model is a multivariate multiple regression. Example . A doctor has collected data on cholesterol, blood pressure, and weight.  She also collected data on the eating habits of the subjects (e.g., how many ounces of red meat, fish, dairy products, and chocolate consumed per week).  She wants to investigate the relationship between the three measures of health and eating habits.

Conduct a Pharmacoeconomic Evaluation Clinicians may need to conduct a pharmacoeconomic evaluation 1. if there is insufficient literature, 2. if published results cannot be extrapolated to clinical practice, 3. or if building a model is not appropriate. The resources necessary and the type of evaluation conducted will vary depending on the research question and on whether one is conducting a prospective outcomes analysis or a retrospective database analysis.

Advantages and Disadvantages of Retrospective and Prospective Analyses ANALYSIS TYPE ADVANTAGES DISADVANTAGES 1.PROSPECTIVE OBSERVATIONAL ANALYSIS FLEXIBLE EXPENSIVE(TIME&MONEY) OFFER COMPARATIVE DATA DIFFICULT TO CONTROL AND RANDOMIZE. DATA FROM MULTIPLE SOURCE CAN BE USED. SMALL SAMPLE SIZE. LESS EXPENSIVE THAN RANDOMIZED CONTROL TRIALS. PATIENT SELECTION BIAS. 2.RETROSPECTIVE DATABASE ANALYSIS LARGE SAMPLE SIZE INCOSISTENT CODING/UPCODING CAN PROVIDE DATA QUICKLY VARIATION IN DATABASE QUALITY. INEXPENSIVE INABLE TO RANDOMIZE.

STEPS FOR CONDUCTING A PHARMACOECONOMIC EVALUATION 1. Define the Pharmacoeconomic Problem. 2. Assemble a Cross-Functional Study Team. 3. Define the Appropriate Study Perspective. 4. Identify Treatment Alternatives and Outcomes. 5. Identify the Appropriate Pharmacoeconomic Method to Employ. 6. Place a Monetary Value on Treatment Alternatives and Outcomes. 7. Identify Resources to Conduct Study in an Efficient Manner.

CONT… 8.Identify Probabilities that Outcomes May Occur in the Study Population 9. Employ Decision Analysis 10. Discount Costs or Perform a Sensitivity or Incremental Cost Analysis 11. Present Study Results 12. Develop a Policy or an Intervention 13. Implement Policy and Educate Professionals 14. Follow-Up Documentation

Conclusions The principles and methodsof pharmacoeconomics provide the means to quantify the value of pharmacotherapy through balancing costs and outcomes. By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better, more informed decisions regarding the use of pharmaceutical products and services—that is, decisions that ultimately represent the best interests of the patient, the healthcare system, and society.

REFERENCES PHARMACOTHERAPY : A PATHOPHYSIOLOGIC APPROACH WIKIPEDIA

THANK YOU